Benepali etanercept and Flixabi infliximab biosimilar news

Studies conducted by Biogen comparing biosimilar autoimmune drugs Benepali etanercept (SB4) and Flixabi infliximab (SB2) to Enbrel etanercept and Remicade infliximab, respectively, showed that the two biosimilars could lead to

Read the full 303 word article

User Sign In